Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore.
Chronic Disease Epidemiology, Population Health, National Healthcare Group, Singapore.
Pharmacoepidemiol Drug Saf. 2020 May;29(5):538-549. doi: 10.1002/pds.4981. Epub 2020 Mar 19.
This retrospective cohort study aims to examine adherence to secondary stroke preventive medications and their association with risk of stroke recurrence and mortality in patients after first-ever ischemic stroke.
Using data from the National Healthcare Group and Singapore Stroke Registry, patients with first-ever ischemic stroke between 2010 and 2014 were included, and categorized based on antithrombotic or statin adherence using the proportion of days covered: high (≥75%), intermediate (50%-74%), low (25%-49%), and very low (<25%). The primary outcome was first recurrent ischemic stroke within a year after hospital discharge, while the secondary composite outcomes were (a) stroke recurrence and all-cause mortality and (b) stroke recurrence and cardiovascular mortality. The Cox proportional hazard model was used to examine the association between medication adherence and outcomes. Adjusted hazard ratios (aHRs) and the corresponding 95% confidence intervals (CIs) were reported.
Among ischemic stroke patients prescribed with antithrombotics (n = 1139) or statins (n = 1160) at hospital discharge, about one-third were highly adherent to their medications. Patients with lower medication adherence tended to be younger, were admitted to private ward classes, and were without hypertension. Compared with the patients with high medication adherence, the risk of stroke recurrence was higher in patients with very low antithrombotic (aHR = 4.65; 95% CI: 1.45-14.89) or statin (aHR = 3.44; 95% CI: 0.93-12.74) adherence. Similar findings were observed for the secondary outcomes.
Poor adherence to antithrombotic and statin treatment increases the risk of recurrent stroke and mortality in patients after first-ever ischemic stroke. Further measures are needed to improve medication adherence among stroke survivors.
本回顾性队列研究旨在探讨首次缺血性卒中后患者二级预防药物的依从性及其与卒中复发和死亡风险的关系。
利用国家医疗保健集团和新加坡卒中登记处的数据,纳入了 2010 年至 2014 年间首次发生缺血性卒中的患者,并根据抗血小板或他汀类药物的依从性(采用覆盖天数比例)进行分类:高(≥75%)、中(50%-74%)、低(25%-49%)和极低(<25%)。主要结局为出院后 1 年内首次复发性缺血性卒中,次要复合结局为(a)卒中复发和全因死亡率和(b)卒中复发和心血管死亡率。采用 Cox 比例风险模型分析药物依从性与结局之间的关系。报告了调整后的危险比(aHR)及其相应的 95%置信区间(CI)。
在出院时接受抗血小板药物(n=1139)或他汀类药物(n=1160)治疗的缺血性卒中患者中,约有三分之一的患者高度依从药物治疗。药物依从性较低的患者往往年龄较小,入住私人病房,且无高血压。与药物高度依从的患者相比,抗血小板药物(aHR=4.65;95%CI:1.45-14.89)或他汀类药物(aHR=3.44;95%CI:0.93-12.74)依从性极低的患者卒中复发风险更高。对于次要结局也观察到类似的结果。
抗血小板和他汀类药物治疗依从性差会增加首次缺血性卒中后患者发生复发性卒中和死亡的风险。需要采取进一步措施提高卒中幸存者的药物依从性。